Objectives: To determine the MIC distributions of itraconazole, voriconazole and posaconazole and non-azole drugs for wild-type cyp51A, as well as TR 34 /L98H and TR 46 /Y121F/T289A cyp51A mutants of Aspergillus fumigatus.
Introduction
Azole resistance in Aspergillus fumigatus is an emerging health concern in many clinical settings. In the Netherlands, two cyp51A gene mutations are largely responsible for this emerging resistance, and are considered to have arisen through azole exposure in the environment. 1 These resistance mechanisms consist of combinations of a tandem repeat in the cyp51A promoter and a concomitant mutation in the cyp51A gene itself, i.e. the 34 bp tandem repeat/L98H mutation combination (TR 34 /L98H) and the 46 bp tandem repeat/Y121F/T289A mutation combination (TR 46 /Y121F/T289A). 1 The presence of these mutations and the resulting MICs of the three major azole drugs (itraconazole, voriconazole and posaconazole) have been studied in small case series, often in specific patient populations. 2, 3 To date, the azole MIC distributions for wild-type cyp51A, but particularly TR 34 /L98H and TR 46 /Y121F/ T289A cyp51A mutants of A. fumigatus, measured by EUCAST methodology, 4 have not been characterized in large strain collections.
We have performed a retrospective analysis of MIC distributions and cyp51A sequence analyses for all A. fumigatus submitted to our national reference laboratory in the 2010 -13 period.
Methods
MICs and cyp51A sequence data for A. fumigatus strains isolated from clinical specimens in or referred to our reference laboratory, during the # The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2015; 70: 178 -181 doi:10.1093/jac/dku364 Advance Access publication 9 October 2014 January 2010 to January 2014 period, were retrieved. Only one isolate per patient per 6 months was included, unless strains exhibited .4-fold differences in the MICs of more than two drugs tested. Identification as A. fumigatus was achieved through morphological examination and growth at 488C and, for azole-resistant isolates, confirmed by the presence and sequence of the cyp51A gene.
All MICs were determined using the EUCAST methodology, i.e. broth microdilution in RPMI1640 medium with 2% glucose and MOPS buffer, with a 1 -2.5×10 5 cfu/mL inoculum and a 48 h incubation. 4 The A. fumigatus ATCC 204305 reference strain was used for quality control.
For all strains with azole MICs in the resistant range (i.e. MIC .2 mg/L for itraconazole or voriconazole or MIC .0.25 mg/L for posaconazole), cyp51A gene and promoter region sequence analysis was performed using previously published methods. 5, 6 The promoter region and cyp51A gene were amplified separately and sequenced using previously published primer sets, which are specific for A. fumigatus. 7 The obtained cyp51A sequences were compared with the cyp51A sequence available through GenBank (accession number AF338659).
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Results and discussion
Nine-hundred and fifty-two A. fumigatus strains met our inclusion criteria. The MIC distributions of itraconazole, voriconazole and posaconazole are presented in Figure 1 .
Three-hundred and sixty-four strains (38%) were subjected to cyp51A gene mutation analyses because of azole MICs in the resistant range. Of these 364, 225 (62% of all azole-resistant isolates; 24% of the 952 studied isolates) contained the TR 34 /L98H mutation and 98 (27% of all azole-resistant isolates; 10% of the 952 studied isolates) contained the TR 46 /Y121F/T289A mutation. The azole MIC distributions for these strains are given in Figure 2 The TR 46 /Y121F/T289A mutants show high-level resistance to voriconazole, high-level resistance or, sporadically, low-level resistance to itraconazole and low-level resistance to posaconazole (Figure 2b ). These MIC distributions are similar to those A. fumigatus azole MIC distribution reported in a small series of 21 isolates isolated in the year 2010 in the Netherlands. 6 In our larger dataset, there is a bimodal pattern in the MIC distribution of itraconazole (Figure 2b) . A subset of these isolates has MICs in the 1 -4 mg/L range, whereas the majority have MICs of 16 or .16 mg/L. The previous study also observed itraconazole MICs close to the breakpoint in TR 46 / Y121F/T289A mutant A. fumigatus, 6 but the small sample size did not permit the identification of the bimodal pattern in itraconazole MIC distribution. The mechanisms underlying these two resistance phenotypes are not known. One hypothesis could be that the TR 46 /Y121F/T289A mutations alone lead to MICs in the 1 -4 mg/L range, with additional mutations in other genes or generic mechanisms such as increased efflux pump activity causing the itraconazole high-level resistance phenotype. A stepwise increase in MICs has been reported for isogenic isolates recovered over time in azole-treated patients, 7 supporting the development of consecutive resistance mechanisms in A. fumigatus when azole exposure continues.
Thirty-nine azole-resistant A. fumigatus strains had wild-type cyp51A and promoter sequences; two had mutations in the cyp51A gene only. In one this was a P216L mutation with MICs of .16 mg/L (itraconazole), 1 mg/L (voriconazole) and .16 mg/L (posaconazole); in the other there were F46Y, Q88H, M172V and E427K mutations, with MICs of 0.5 mg/L (itraconazole), 2 mg/L (voriconazole) and 0.125 mg/L (posaconazole). Azole MIC distributions for these 41 isolates are recorded in Figure 2(c) ; the values of MIC 50 and MIC 90 of all studied compounds are given in Table 1 . These azole-resistant strains show highly variable MICs (Figure 2c ), which suggests that multiple, but currently unknown, mechanisms underlie their azole-resistance phenotype. Recent studies showed a novel mechanism involved in azole resistance of A. fumigatus, being mutations in the hapE gene and increased expression of the c1b efflux pump and the cyp51B gene, 1 but these are probably just the tip of the iceberg. One isolate had a T95 C nucleotide polymorphism in the promoter and F46Y, M172V and E427K mutations in the cyp51A gene; this strain had azole MICs of .16 mg/L (itraconazole), 8 mg/L (voriconazole) and 2 mg/L (posaconazole).
The values of MIC 50 and MIC 90 of the azoles, amphotericin B, terbinafine and anidulafungin for TR 34 /L98H and TR 46 /Y121F/ T289A, the azole-resistance phenotype not caused by these two mutations, and azole-susceptible A. fumigatus are recorded in Table 1 . The in vitro activity of amphotericin B and anidulafungin was not affected by the presence of azole-resistance mechanisms, and terbinafine was generally not active. The observed MIC distributions and MIC 50 and MIC 90 values did not change over time for any drug in any subgrouping based on azole susceptibilities.
The variable MIC profiles indicate that resistance might be missed if screening is performed using a single azole drug, as was common in early surveillance studies. 5, 8 More recent studies have used screening agar that included three azoles (itraconazole, voriconazole and posaconazole), thereby reducing the risk of missing azole-resistant isolates. 6 Molecular detection of azole-resistance mechanisms directly in clinical specimens has been proposed for tailoring antifungal treatment. 10 Such an approach might be successful provided that the phenotype can be reliably predicted based on the resistance mutation that is detected. For TR 34 /L98H strains with MICs at or just above the breakpoint, increased voriconazole doses could still be effective. Similarly, high-dose itraconazole therapy may be effective against TR 46 /Y121F/T289A strains with itraconazole MICs at or just above the breakpoint. On the other hand, 41 of the 364 (11%) azole-resistant A. fumigatus isolates had wild-type cyp51A sequences or mutations other than TR 34 /L98H and TR 46 / Y121F/T289A and likely would have been missed by direct molecular detection.
This study has two important limitations. First, we did not have information on clinical significance or prior azole exposure for the studied isolates; there is likely a referral bias towards azole-resistant isolates or isolates associated with treatment failure. Second, we did not systematically perform molecular identification of isolates identified as A. fumigatus. Although all isolates were able to grow at 488C, we cannot exclude the presence of closely related sibling species within the A. fumigatus species complex among the azole-susceptible isolates.
In summary, we studied the MIC distributions of azole and nonazole drugs for a large collection of A. fumigatus isolates and were able to further characterize the MIC profiles associated with the TR 34 /L98H and TR 46 /Y121F/T289A resistance mechanisms.
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